You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Around the Region

Bluebird bio advances drug study

Bluebird bio Inc., a Cambridge gene therapy company that had an initial public stock offering in June, said Monday the first patient has undergone infusion with its Lenti-D drug product in a stem cell transplantation.

The company, which looks to develop next generation products to treat patients with severe genetic and orphan diseases, has been working on a therapy to slow the progression of a genetic brain disorder called childhood cerebral adrenoleukodystrophy, or CCALD.

Continue reading below

In a Monday press release, bluebird bio said that the first subject in its phase 2/3 study had undergone infusion with the drug in an autologous hematopoietic stem cell transplantation.

In June, shares of bluebird bio soared nearly 60 percent on their first day of public trading.

Bluebird bio is one of more than half a dozen Massachusetts biotech companies that have gone public so far this year, including Enanta Pharmaceuticals Inc. and Tetraphase Pharmaceuticals Inc. of Watertown and Cambridge-based Epizyme Inc., Agios Pharmaceuticals Inc., and Acceleron Pharma Inc.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.